Dr. Isabel Adrados, PhD, is currently a Research Associate at The Scripps Research Institute, Florida, where she studies the role of autophagy in glioblastoma’s resistance to radiotherapy, both in vivo and in vitro. Her research is focused on 1) dissecting the autophagy pathway in the radio-resistance process, and 2) developing a small molecule to be used in combination with irradiation or other existing drugs against glioblastoma. She did her PhD at the Institute of Biomedical Research, in Madrid. Here, she discovered a novel role of SIX1, a homeobox transcription factor, as an epigenetic repressor of p16, an important tumor suppressor gene. During this time she did a stage at the Imperial College of London, where she also investigated the role of SIX1 in cell reprogramming. Her most relevant research previous to her PhD, is in cancer and cannabinoids during an internship, in San Francisco, at the California Pacific Medical Center, Research Institute, where she studied the antitumoral effect of cannabidiol, both in breast and brain cancer.

Cell Senescence; Drug Discovery; Pharmacology; Cancer Biology; Autophagy; DNA Damage.